These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8926578)

  • 1. Isomerization and formulation stability of the vaccine adjuvant QS-21.
    Cleland JL; Kensil CR; Lim A; Jacobsen NE; Basa L; Spellman M; Wheeler DA; Wu JY; Powell MF
    J Pharm Sci; 1996 Jan; 85(1):22-8. PubMed ID: 8926578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy.
    Jacobsen NE; Fairbrother WJ; Kensil CR; Lim A; Wheeler DA; Powell MF
    Carbohydr Res; 1996 Jan; 280(1):1-14. PubMed ID: 8581890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes.
    Brunner L; Barnier-Quer C; Collin N
    Methods Mol Biol; 2017; 1494():73-86. PubMed ID: 27718186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex.
    Kensil CR; Patel U; Lennick M; Marciani D
    J Immunol; 1991 Jan; 146(2):431-7. PubMed ID: 1987271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QS-21 and QS-7: purified saponin adjuvants.
    Kensil CR; Wu JY; Anderson CA; Wheeler DA; Amsden J
    Dev Biol Stand; 1998; 92():41-7. PubMed ID: 9554258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in saponin-based adjuvants.
    Sun HX; Xie Y; Ye YP
    Vaccine; 2009 Mar; 27(12):1787-96. PubMed ID: 19208455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
    Deng K; Adams MM; Gin DY
    J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function relationship among Quillaja saponins serving as excipients for nasal and ocular delivery of insulin.
    Pillion DJ; Amsden JA; Kensil CR; Recchia J
    J Pharm Sci; 1996 May; 85(5):518-24. PubMed ID: 8742944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant activity of QS-21 isomers.
    Soltysik S; Bedore DA; Kensil CR
    Ann N Y Acad Sci; 1993 Aug; 690():392-5. PubMed ID: 8368766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi.
    Kim YJ; Wang P; Navarro-Villalobos M; Rohde BD; Derryberry J; Gin DY
    J Am Chem Soc; 2006 Sep; 128(36):11906-15. PubMed ID: 16953631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria.
    Kensil CR; Soltysik S; Wheeler DA; Wu JY
    Adv Exp Med Biol; 1996; 404():165-72. PubMed ID: 8957293
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis and Evaluation of QS-7-Based Vaccine Adjuvants.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    ACS Infect Dis; 2019 Jun; 5(6):974-981. PubMed ID: 30920199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QS-21 structure/function studies: effect of acylation on adjuvant activity.
    Liu G; Anderson C; Scaltreto H; Barbon J; Kensil CR
    Vaccine; 2002 Jun; 20(21-22):2808-15. PubMed ID: 12034108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a novel saponin adjuvant derived from Quillaja saponaria on the immune response to recombinant hepatitis B surface antigen.
    So HS; Yoon HS; Choi DY; Kwon YS; Sung JH; Lee TG; Park ES; Cho HS; Lee BM; Cho JM; Ryu WS
    Mol Cells; 1997 Apr; 7(2):178-86. PubMed ID: 9163729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of the potent immunostimulatory adjuvant QS-21A.
    Wang P; Kim YJ; Navarro-Villalobos M; Rohde BD; Gin DY
    J Am Chem Soc; 2005 Mar; 127(10):3256-7. PubMed ID: 15755124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of a QS-17/18-Based Vaccine Adjuvant.
    Wang P; Škalamera Đ; Sui X; Zhang P; Michalek SM
    J Med Chem; 2019 Feb; 62(3):1669-1676. PubMed ID: 30656932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.
    Soltysik S; Wu JY; Recchia J; Wheeler DA; Newman MJ; Coughlin RT; Kensil CR
    Vaccine; 1995; 13(15):1403-10. PubMed ID: 8578817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomic model and micelle dynamics of QS-21 saponin.
    Pedebos C; Pol-Fachin L; Pons R; Teixeira CV; Verli H
    Molecules; 2014 Mar; 19(3):3744-60. PubMed ID: 24662086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
    Fernández-Tejada A; Tan DS; Gin DY
    Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.